# A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small

Source: https://onco.cc/trials/nct07005128/  
OnCo record `nct07005128` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tarlatamab, Durvalumab, Carboplatin in small-cell lung cancer, run by Amgen, active and no longer recruiting.

## Summary

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) is a phase 3 interventional study registered as NCT07005128 by Amgen, with 350 participants enrolled, started 2025-08-18 and due to reach its primary completion in 2029-01-04. Interventions recorded: Tarlatamab, Durvalumab, Carboplatin, Etoposide. Conditions listed: Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07005128
- Phase: 3
- Setting: A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
- Sponsor: Amgen
- Enrolled: 350

## Sources

- ClinicalTrials.gov NCT07005128: https://clinicaltrials.gov/study/NCT07005128

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Etoposide](https://onco.cc/drugs/etoposide/), [Tarlatamab](https://onco.cc/drugs/tarlatamab/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct07005128.json